Introduction Trigone Pharma Ltd. is a privately-owned corporation headquartered in Raanana, Israel, which specializes in the production of pharmaceuticals. The company's primary objective is to enhance the quality of life for patients with bladder diseases that have not yet been adequately addressed by current medical treatments. By utilizing their exclusive technology, Trigone Pharma is developing groundbreaking therapies for a range of diseases that impact millions of individuals worldwide. Their lead product, TRG-100, is a novel, long-acting treatment that combines two medications for the intravesical treatment of IC/BPS, a chronic bladder condition characterized by severe pain. The company's pipeline also includes potential treatments for overactive bladder, renal colic, and bladder cancer. |